KRSA

NASD Korsana Biosciences, Inc.
Oct 7, 2026 · 7:03 PM ET LAST TRADE Market Closed

$31.30 ↓ -0.35 (-1.11%) Trading Down from the previous close of $31.65, $1.10 below the day’s high of $32.40

YTD change
+19.47%
vs 20-day SMA
-1.57%
vs 200-day SMA
N/A

Price ranges

Previous day
$30.50 $31.92
open $30.50 close $31.77
+$1.27 (+4.16%)
Today
$31.00 $32.40
open $32.36 now $31.30
-$1.06 (-3.28%)
Past week
$29.50 $34.33
from $34.00 now $31.30
-$2.70 (-7.94%)
Past month
$21.00 $37.27
from $26.20 now $31.30
+$5.10 (+19.47%)
This year
$21.00 $37.27
from $26.20 now $31.30
+$5.10 (+19.47%)

Price & Performance

+5.57 (+21.26%) / 6M

$23.55$28.43$33.32$38.20Sep 9Sep 22Oct 6

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Neutral
  • The stock is 16.0% away from all-time highs of $37.27
  • KRSA is up 19% since the beginning of the year
  • KRSA is up 19% over the past 12 months
  • KRSA is up 19% over the past 1 month
  • 0% of all KRSA investors are betting against KRSA

KRSA reads neutral: the 12-month move is +21.3%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-3.42
Earnings momentum -303.8% Quarterly EPS growth
Quarterly change -303.8%

Valuation

P/E ratio N/A
Enterprise value $17.9M
Beta 1.39

Balance sheet & scale

IncomeN/A
Revenue$1.9M
Cash$1.4M
DebtN/A
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Market cap $1.4B

Korsana Biosciences, Inc. is a biopharmaceutical company, which engages in discovering and developing novel therapies to reduce the burden of neurodegenerative diseases. Its portfolio includes the KRSA-028 pipeline. The company was founded in 2024 and is headquartered in Waltham, MA.

Competitor comparison

No peer group available for this symbol.

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.